Established donepezil treatment modulates regional brain activation in early alzheimer's disease

Current Alzheimer Research

Volumn 7, Issue 5, 2010, Pages 415-427

  Mcgeown, W J ^a   Shanks, M F ^a   Forbes Mckay, K E ^b   Waiter, G D ^c   Elrick, I ^d   Venneri, M G ^e   Venneri, A ^a,e  

^a UNIVERSITY OF HULL   (United Kingdom)

^b ROBERT GORDON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NHS GRAMPIAN   (United Kingdom)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Fmri; Pharmacodynamic; Semantic; Upregulation; Working memory

Indexed keywords

DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD OXYGENATION; BRAIN FUNCTION; BRAIN STEM; CAUDATE NUCLEUS; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE TITRATION; EXPLORATORY RESEARCH; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INSULA; MALE; PARAMETRIC TEST; PARIETAL LOBE; PRIORITY JOURNAL; SEMANTICS; TASK PERFORMANCE; THALAMUS; TREATMENT DURATION; WORKING MEMORY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; FEMALE; HUMANS; INDANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; REACTION TIME; TREATMENT OUTCOME;

EID: 78549258480     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510791383877     Document Type: Article

References (33)

1. Venneri A. Imaging treatment effects in Alzheimer's disease. Magn Reson Imaging 25: 953-68 (2007).
2. Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 13: 83-7 (2002).
3. Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 43: 983-90 (2002).
4. Nobili F, Vitali P, Canfora M, Girtler N, De Leo C, Mariani G, et al. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 113: 1241-8 (2002).
5. Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol 4: 223-30 (2001).
6. Stefanova E, Wall A, Almkvist O, Nilsson A, Forsberg A, Langstrom B, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm 113: 205-18 (2006).
7. Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci 216: 119-26 (2003).
8. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Langstrom B, Nordberg A. Changes in brain (11)C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) 191: 1005-14 (2007).
9. Rombouts SA, Barkhof F, Van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 73: 665-71 (2002).
10. Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 127: 1574-83 (2004).
11. Kircher TT, Erb M, Grodd W, Leube DT. Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study. Am J Geriatr Psychiatry 13: 1006-13 (2005).
12. Goekoop R, Rombouts SA, Jonker C, Hibbel A, Knol DL, Truyen L, et al. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. Neuroimage 23: 1450-9 (2004).
13. Goekoop R, Scheltens P, Barkhof F, Rombouts SA. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study. Brain 129: 141-57 (2006).
14. Gron G, Brandenburg I, Wunderlich AP, Riepe MW. Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiol Aging 27: 78-87 (2006).
15. Venneri A, McGeown WJ, Shanks MF. Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation. Curr Alzheimer Res 6: 97-111 (2009).
16. Shanks MF, McGeown WJ, Forbes-McKay KE, Waiter GD, Ries M, Venneri A. Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease. Magn Reson Imaging 25: 848-59 (2007).
17. McGeown WJ, Shanks MF, Venneri A. Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease. Neuropsychiatr Dis Treat 4: 465-76 (2008).
18. Price CJ, Friston KJ. Scanning patients with tasks they can perform. Hum Brain Mapp 8: 102-8 (1999).
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-44 (1984).
20. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr 9: 65-9 (1997).
21. Hachinski VC, Iliff LD, Zilhka E, DuBoulay GH, McAllister VL, Marshall J, et al. Cerebral blood flow in dementia. Arch Neurol 32: 632-637 (1975).
22. Folstein MF, Folstein SE, McHugh PR. Mini-Mental-State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
23. Brun A, Englund B, Gustafson L, Passant V, Mann DMA, Neary D, et al. Clinical and Neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 57: 416-418 (1994).
24. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124 (1996).
25. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250-60 (1993).
26. Howard D, Patterson K. The Pyramids and Palm Trees Test. Suffolk, VA: Thames Valley Test Co. (1992).
27. Lane RM, Kivipelto M, Greig NH. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 27: 141-9 (2004).
28. Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 6: 4-14 (2009).
29. De Sarno P, Giacobini E. Modulation of acetylcholine release by nicotinic receptors in the rat brain. J Neurosci Res 22: 194-200 (1989).
30. Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Differential increase in cerebrospinal fluidacetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 300: 157-60 (2001).
31. Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellstrom Lindahl E, Andreasen N, et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm 113: 1791-801 (2006).
32. Frolich L. The cholinergic pathology in Alzheimer's disease discrepancies between clinical experience and pathophysiological findings. J Neural Transm 109: 1003-13 (2002).
33. Singh S, Dudley C Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 18: 282-4 (2003).